Virtu Financial LLC Takes $28,000 Position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

Virtu Financial LLC bought a new position in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 16,604 shares of the company’s stock, valued at approximately $28,000.

Other large investors have also added to or reduced their stakes in the company. The Manufacturers Life Insurance Company bought a new stake in shares of Nautilus Biotechnology in the third quarter worth $67,000. SG Americas Securities LLC grew its stake in shares of Nautilus Biotechnology by 56.3% during the 4th quarter. SG Americas Securities LLC now owns 27,483 shares of the company’s stock valued at $46,000 after purchasing an additional 9,904 shares during the period. Palumbo Wealth Management LLC increased its position in shares of Nautilus Biotechnology by 45.4% during the 4th quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company’s stock valued at $48,000 after purchasing an additional 8,888 shares during the last quarter. MetLife Investment Management LLC bought a new position in shares of Nautilus Biotechnology in the 3rd quarter worth approximately $87,000. Finally, Barclays PLC boosted its holdings in shares of Nautilus Biotechnology by 79.6% in the third quarter. Barclays PLC now owns 106,174 shares of the company’s stock worth $303,000 after buying an additional 47,059 shares during the last quarter. Institutional investors own 50.71% of the company’s stock.

Nautilus Biotechnology Price Performance

Shares of NAUT stock opened at $0.83 on Wednesday. Nautilus Biotechnology, Inc. has a one year low of $0.82 and a one year high of $3.09. The company has a market capitalization of $104.72 million, a price-to-earnings ratio of -1.48 and a beta of 1.25. The company’s fifty day moving average price is $1.40 and its 200-day moving average price is $2.02.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Guggenheim set a $2.50 price target on shares of Nautilus Biotechnology in a research report on Friday, February 28th. The Goldman Sachs Group cut Nautilus Biotechnology from a “neutral” rating to a “sell” rating and decreased their target price for the stock from $2.25 to $1.75 in a report on Thursday, December 5th.

Insider Buying and Selling at Nautilus Biotechnology

In other news, CEO Sujal M. Patel purchased 53,300 shares of the company’s stock in a transaction that occurred on Wednesday, March 19th. The stock was bought at an average cost of $0.99 per share, with a total value of $52,767.00. Following the completion of the purchase, the chief executive officer now owns 10,117,788 shares in the company, valued at approximately $10,016,610.12. This represents a 0.53 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 40.50% of the company’s stock.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.